A selective estrogen receptor degrader or downregulator (SERD) is a type of drug which binds to the estrogen receptor (ER) and, in the process of doing so, causes the ER to be degraded and thus downregulated.[1] They are used to treat estrogen receptor-sensitive or progesterone receptor-sensitive breast cancer, along with older classes of drugs like selective estrogen receptor modulators (SERMs) and aromatase inhibitors.[1]
As of 2016 the only marketed SERD was fulvestrant (brand name Faslodex).[1] As of November 2016 other SERDs under development include brilanestrant and elacestrant.[2] The clinical success of fulvestrant led to efforts to discover and develop a parallel drug class of selective androgen receptor degraders (SARDs).[2]
Investigational[edit]
Fulvestrant requires large-volume and frequently painful intramuscular injections.[3] In response, pharmaceutical companies are currently developing oral SERDs. Among products in development are:[4]
- Giredestrant: Roche
- Amcenestrant (SAR439859): Sanofi
- Camizestrant (AZD9833): AstraZeneca
- Rintodestrant (G1T48) : G1 Therapeutics
- LSZ102: Novartis
- Imlunestrant (LY3484356): Eli Lilly
- Elacestrant: Radius
- ZN-c5: Zentalis
- Taragarestrant (D-0502): Inventisbio
- SHR9549: Jiangsu Hengrui
- Vepdegestrant (ARV-471): Oral estrogen receptor PROTAC protein degrader for breast cancer by Arvinas.
- ZB716 (Fulvestrant boronic acid).
- Brilanestrant: Genentech
- Etacstil: combined SERM and SERD
- [[Palazestrant]]
The oral SERDs target ER-positive/HER2-negative breast cancer and are tested as monotherapy and in combination with other drugs such as the CDK inhibitor palbociclib (Ibrance).[5][6][7]
See also[edit]
References[edit]
- ^ a b c Lee, Clara I; Goodwin, Annabel; Wilcken, Nicholas (3 January 2017). "Fulvestrant for hormone-sensitive metastatic breast cancer". Cochrane Database of Systematic Reviews. 2017 (1): CD011093. doi:10.1002/14651858.CD011093.pub2. PMC 6464820. PMID 28043088.
- ^ a b Lai, Ashton C.; Crews, Craig M. (February 2017). "Induced protein degradation: an emerging drug discovery paradigm". Nature Reviews Drug Discovery. 16 (2): 101–114. doi:10.1038/nrd.2016.211. PMC 5684876. PMID 27885283.
- ^ "Injection-Site Pain With Large-Volume Intramuscular Injection of Fulvestrant Can Be Minimized". PracticeUpdate. Retrieved 2020-12-28.
- ^ "A blockbuster breast cancer niche has Roche and Sanofi in the lead". Evaluate.com. 2020-02-19. Retrieved 2020-12-28.
- ^ "Rintodestrant | oral selective estrogen receptor degrader (SERD) | G1 Therapeutics, Inc". www.g1therapeutics.com. Retrieved 2021-01-09.
- ^ Nalley, Catlin (5 February 2021). "Orally Bioavailable SERD Shows Promise in Certain Breast Cancer Patients". Oncology Times. 43 (3): 35. doi:10.1097/01.COT.0000734348.58210.24.
- ^ Bardia, Aditya; Linden, Hannah M.; Ulaner, Gary A.; Chandarlapaty, Sarat; Gosselin, Alice; Celanovic, Marina; Campone, Mario (20 May 2019). "Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic breast cancer". Journal of Clinical Oncology. 37 (15_suppl): TPS1105. doi:10.1200/JCO.2019.37.15_suppl.TPS1105. S2CID 190898194.
Well, that’s interesting to know that Psilotum nudum are known as whisk ferns. Psilotum nudum is the commoner species of the two. While the P. flaccidum is a rare species and is found in the tropical islands. Both the species are usually epiphytic in habit and grow upon tree ferns. These species may also be terrestrial and grow in humus or in the crevices of the rocks.
View the detailed Guide of Psilotum nudum: Detailed Study Of Psilotum Nudum (Whisk Fern), Classification, Anatomy, Reproduction